Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Zim Laboratories Ltd

Pharmaceuticals & Biotechnology | Small Cap

Zim Laboratories Ltd Health Insights
Health Score : 5.41Health Score : 5.41

Zim Laboratories shows a mixed financial landscape. Revenue and asset growth are strong, alongside solid profitability driven by good gross profit and returns on assets and capital employed. The company maintains a strong equity position, indicating financial stability. However, liquidity is poor, with low current, quick, and cash ratios. Efficiency ratios are also weak, suggesting challenges in asset utilization. EPS and net income growth are concerning. While coverage ratios are mixed, with a reasonable interest coverage, the company does not distribute dividends. This overview suggests a need to address liquidity and efficiency while capitalizing on growth and profitability.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Zim Laboratories Ltd Health Insights
Health Score : 5.41Health Score : 5.41

Zim Laboratories shows a mixed financial landscape. Revenue and asset growth are strong, alongside solid profitability driven by good gross profit and returns on assets and capital employed. The company maintains a strong equity position, indicating financial stability. However, liquidity is poor, with low current, quick, and cash ratios. Efficiency ratios are also weak, suggesting challenges in asset utilization. EPS and net income growth are concerning. While coverage ratios are mixed, with a reasonable interest coverage, the company does not distribute dividends. This overview suggests a need to address liquidity and efficiency while capitalizing on growth and profitability.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Neutral

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Neutral

P/E RATIO (TTM)

77.71

Overvalued

Industry Median

23.93

Overvalued
Overvalued

Small Cap Median

23.93

Overvalued

P/E RATIO

41.96

P/B RATIO

2.03

Undervalued

Industry Median

2.53

Undervalued
Undervalued

Small Cap Median

2.53

Undervalued

P/S RATIO

1.35

Highly Undervalued

Industry Median

1.35

Highly Undervalued
Undervalued

Small Cap Median

1.35

Undervalued

Others

Neutral

PEG RATIO

1.41

Neutral
Neutral

EV/EBITDA RATIO

10.43

Neutral

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹104.91 as on Jun 15, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 6.00

The company has strong revenue and asset growth. However, the negative earnings per share (EPS) growth and net income growth are concerning. The company's growth trajectory is promising in terms of revenue and assets, but profitability needs to catch up to ensure sustainable expansion.

ExcellentRevenue Growth RateExcellent
ExcellentOperating Profit Growth RateExcellent
PoorEarnings Per Share (EPS) GrowthPoor
ExcellentAsset Growth RateExcellent
PoorNet Income Growth RatePoor
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate8.4719.82-8.023.27-1.32
Operating Profit Growth Rate2.526.83-21.157.32-31.82
Earnings Per Share (EPS) Growth99.3367.56-29.34-29.38-56.4
Asset Growth Rate5.23030.75.5914.19
Net Income Growth Rate114.2960-29.17-29.41-50
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 4.00

Financial ratios indicate areas of concern. Adjusted earnings per share and book value per share are low, while cash earnings per share is somewhat better. The company makes no dividend payments and has significant capital expenditures. It should focus on improving these financial metrics to bolster investor confidence and long-term sustainability.

PoorAdjusted Earnings Per Share (Adjusted EPS)Poor
WeakCash Earnings Per Share (Cash EPS)Weak
PoorBook Value Per SharePoor
PoorDividend Per Share (DPS)Poor
ExcellentCapital Expenditures (CapEx)Excellent
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)9.384.93.472.450.93
Cash Earnings Per Share (Cash EPS)19.388.376.736.534.81
Book Value Per Share109.3841.0248.7851.6355
Dividend Per Share (DPS)00000
Capital Expenditures (CapEx)15.136.673.440.138.8
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 7.20

The company's profitability ratios show strengths and weaknesses. Gross profit margin, return on capital employed (ROCE), return on assets (ROA), and operating margin are robust. Return on equity (ROE) and net margin are low. The company is generating good returns on its capital and assets, but struggles to translate this into net profits and equity returns. Improving net margin and ROE should be a priority.

ExcellentGross Profit MarginExcellent
ExcellentReturn on Capital Employed (ROCE)Excellent
PoorReturn on Equity (ROE)Poor
ExcellentReturn on Assets (ROA)Excellent
ExcellentOperating MarginExcellent
PoorNet MarginPoor
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin7.518.776.816.332.67
Return on Capital Employed (ROCE)12171085
Return on Equity (ROE)8.5711.947.114.742.02
Return on Assets (ROA)11.9915.29.179.325.57
Operating Margin12.3113.0311.1711.618.02
Net Margin4.56.024.633.171.6
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 4.67

Efficiency ratios reveal mixed performance. While days sales in inventory and receivable days are high, suggesting effective working capital management, the fixed asset and capital turnover ratios are low. The company may not utilize its assets efficiently to generate revenue. While specific to the healthcare industry, addressing asset utilization could unlock further value.

PoorFixed Asset Turnover RatioPoor
PoorInventory Turnover RatioPoor
PoorReceivables Turnover RatioPoor
ExcellentDays Sales in Inventory RatioExcellent
ExcellentReceivable DaysExcellent
PoorCapital Turnover RatioPoor
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio3.143.662.282.312.31
Inventory Turnover Ratio4.785.645.074.254.04
Receivables Turnover Ratio4.114.313.763.663.46
Days Sales in Inventory Ratio76.3664.7271.9985.8890.35
Receivable Days88.8184.6997.0799.73105.49
Capital Turnover Ratio1.71.741.311.271.09
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 5.60

The company's coverage ratios present a mixed picture. The interest coverage ratio is adequate, indicating the company can meet its interest obligations. The absence of dividend payments results in a low equity dividend coverage ratio. The ability to comfortably cover interest expenses is a positive sign, while dividend policies reflect capital allocation decisions.

GoodInterest Coverage RatioGood
PoorEquity Dividend Coverage RatioPoor
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage Ratio3.626.834.432.641.62
Equity Dividend Coverage Ratio
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

The company's solvency position appears strong, characterized by a high equity ratio and low debt ratios, indicating a reliance on equity financing rather than debt. While a debt-free status can be seen as a positive, it might also suggest missed opportunities for leveraging debt to fuel growth. The company's financial structure appears conservative, focusing on maintaining a strong equity base.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0.110.120.150.150.13
Debt to Equity Ratio0.120.140.180.180.15
Equity Ratio0.890.880.850.850.87
Debt To Asset Ratio0.060.080.090.10.09
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 2.00

The company's liquidity position is weak, indicating potential difficulties in meeting short-term obligations. The current, quick, and cash ratios are notably low, suggesting limited liquid assets. On a positive note, the company's operating cash flow might provide some support. The healthcare industry's specific working capital needs should be considered, but the low ratios raise concerns about financial flexibility.

PoorCurrent RatioPoor
PoorQuick RatioPoor
PoorCash RatioPoor
PoorOperating Cash Flow RatioPoor
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio1.561.811.461.361.43
Quick Ratio1.031.330.980.870.95
Cash Ratio0.030.070.060.010.22
Operating Cash Flow Ratio0.340.330.10.240.25
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 14 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Medico Remedies Ltd6.6137.70Overvalued17.001.5813.00
2SMS Lifesciences India Ltd6.5921.78Neutral45.0070.6819.00
3Infinium Pharmachem Ltd6.4226.49Neutral22.006.4314.00
4Medicamen Biotech Ltd5.7331.76Neutral20.006.9410.00
5Aarey Drugs & Pharmaceuticals Ltd5.7358.49Neutral7.001.404.00
6Albert David Ltd5.63-272.76Neutral5.00-2.62-1.00
7BPL Ltd5.46-31.34Neutral-4.82-3.00-8.55
8Zim Laboratories Ltd5.4141.96Neutral30.001.116.00
9Quest Laboratories Ltd5.2711.86Neutral18.009.1615.00
10Sotac Pharmaceuticals Ltd5.2721.26Neutral18.004.456.00
11Lyka Labs Ltd4.77-24.93Neutral-4.00-9.05-10.00
12Krebs Biochemicals & Industries Ltd4.16-5.14Highly Undervalued-4.00-12.49-4.00
13Nectar Lifescience Ltd3.83-2.67Neutral-59.00-2.95-293.00
Management Assessment Summary
OrangeBalanced Management

The management of Zim Laboratories shows a mixed performance. A consistent operating profit margin and stable promoter holding are positive indicators. However, declining profit growth and increasing debt levels raise concerns. The inconsistent quarterly sales and profit growth indicate operational challenges. Despite a stable promoter holding, the financial performance and rising liabilities suggest a need for improvements in financial management and execution.

Category Metric Value Assessment
PROS Operating Profit Margin 12% Stable operational efficiency
Promoter Holding 33.26% Consistent promoter confidence
CONS Profit Growth -6% (3Y) Declining profit growth
Debt/Equity Ratio Increasing Rising financial leverage
AverageFinancial Performance & GrowthAverage
WeakCapital Efficiency & ReturnsWeak
AverageFinancial Health & PrudenceAverage
GoodShareholding & Ownership StructureGood
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Shareholding & Ownership Structure

Risk Assessment Summary
OrangeBalanced Risk

The risk assessment for Zim Laboratories is moderate. The segment performance shows volatility from fluctuating sales and profit growth. This inconsistency raises concerns about the predictability of future earnings. The increasing debt levels also add to the risk profile.

AverageSegment performance volatilityAverage
AverageForeign exchange or interest rate exposureAverage
01.

Segment performance volatility

02.

Foreign exchange or interest rate exposure

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe